Related Experiment Video
Updated: Jun 4, 2026
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a
F M Carozzi1, E Burroni, S Bisanzi
1Analytical Cytology and Biomolecular Unit, ISPO, Cancer Prevention and Research Institute, Florence, Italy. f.carozzi@ispo.toscana.it
Abstract:
Randomized trials have produced sound evidence about the efficacy of screening with human papillomavirus (HPV) DNA tests in reducing cervical cancer incidence and mortality. We evaluated the clinical performance and reproducibility of the Abbott RealTime High Risk (HR) HPV test compared with that of the HR hybrid capture 2 (HC2) assay as assessed by a noninferiority score test. A random sample of 998 cervical specimens (914 specimens of cervical intraepithelial neoplasia less severe than grade 2 [
